DOCSLIB.ORG

Vol 6, No 3 March 2014 ISSN 2072-1439 Indexed in Pubm Ed

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vol 6, No 3 March 2014 ISSN 2072-1439 Indexed in Pubm Ed Journal Thoracic of Disease Vol 6, No 3 March 2014 ISSN 2072-1439 JJOURNALOURNAL ofof TTHORACICHORACIC DDISEASEISEASE www.jthoracdis.com FOCUSED ISSUE: Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery Guest Editors: Loven Moodley, Keertan Dheda Volume 6 Number 3 March 2014 Pages 181-284; E36 6 Number PagesVolume 181-284; 3 March 2014 Published by Pioneer Bioscience Publishing Company Indexed in PubMed, SCI Now Indexed in Pub ed Aims and Scope Address: 9A Gold Shine Tower, 346-348 Queen’s Road The Journal of Thoracic Disease (JTD, J Thorac Dis, pISSN: Central, Sheung Wan, Hong Kong. Tel: +852 3488 1279; 2072-1439; eISSN: 2077-6624) was founded in Dec 2009, Fax: +852 3488 1279. indexed in Pubmed/Pubmed Central in Dec 2011, and Science Email: [email protected] Citation Index (SCI) on Feb 4, 2013. It is published quarterly www.jthoracdis.com (Dec 2009- Dec 2011), bimonthly (Jan 2012- Dec 2013), and monthly (Jan 2014-), and openly distributed worldwide. Note to NIH Grantees JTD publishes manuscripts that describe new findings in the Pursuant to NIH mandate, Pioneer Bioscience Publishing field provide current, practical information on the diagnosis Company will post the accepted version of contributions and treatment of conditions related to thoracic disease (lung authored by NIH grant-holders to PubMed Central upon disease, cardiology and esophagus disease). Original articles acceptance. This accepted version will be made publicly are considered most important and will be processed for rapid available 2 months after publication. For further information, review by the members of Editorial Board. Clinical trial notes, see www.thepbpc.org Cancer genetics reports, Epidemiology notes and Technical notes are also published. Case reports implying new findings Conflict of Interest Policy for Editors that have significant clinical impact are carefully processed for The full policy and the Editors’ disclosure statements are possible publication. Review articles are published in principle available online at: www.jthoracdis.com at the Editor’s request. There is no fee involved throughout the publication process. The acceptance of the article is based on Disclaimer the merit of quality of the manuscripts. All the submission and The Publisher and Editors cannot be held responsible for reviewing are conducted electronically so that rapid review is errors or any consequences arising from the use of information assured. contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, The Official Publication of: neither does the publication of advertisements constitute any v Guangzhou Institute of Respiratory Disease (GIRD) endorsement by the Publisher and Editors of the products v China State Key Laboratory of Respiratory Disease advertised. v First Affiliated Hospital of Guangzhou Medical College v Society for Thoracic Disease (STD) Cover image: Virtual bronchoscopy images of the normal proximal (A) and distal (B) Endorsed by: trachea. (See P262 in this issue). v International COPD Coalition (ICC) For submission instructions, subscription and all other Editorial Correspondence information visit www.jthoracdis.com Daoyuan Wang, MD Managing Editor © 2014 Pioneer Bioscience Publishing Company Pioneer Bioscience Publishing Company Editor-in-Chief Nanshan Zhong, MD Academician, Chinese Academy of Engineering. Guangzhou Institute of Respiratory Disease, Guangzhou, China Executive Editor-in-Chief Jianxing He, MD, FACS The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China Executive Editor-in-Chief (Cardiovascular Surgery) Tristan D. Yan, BSc, MBBS, MS, MD, PhD Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia; The Collaborative Research (CORE) Group, Sydney, Australia Deputy Editors-in-Chief Duarte, USA London, United Kingdom Jin-Shing Chen, MD, PhD Kwun Fong, MBBS (Lon), FRACP, PhD Gaetano Rocco, MD, FRCS (Ed), FETCS, FCCP Taipei, Taiwan Brisbane, Australia Naples, Italy Rongchang Chen, MD, PhD Lawrence Grouse, MD, PhD Guangzhou , China Gig Harbor, USA Yi-Jen Chen, MD, PhD Shahzad G. Raja, MBBS, MRCSEd, FRCSEd (C-Th) Editorial Co-Directors & Executive Editors Statistical Editors Guangqiao Zeng, MD Jiqian Fang, PhD Guangzhou, China Guangzhou, China Daoyuan Wang, MD Baoliang Zhong, MD, PhD Guangzhou, China Hong Kong, China Associate Editors Section Editor (Systematic Section Editor (Cancer Registry, Hatem A Azim Jr, MD Paul Zarogoulidis, MD, PhD Review and Meta-analysis) Prevention and Control) Brussels, Belgium Thessaloniki , Greece Zhi-De Hu, M.M Wanqing Chen, MD Kazuaki Takabe, MD, PhD, FACS Junya Zhu, MS, MA Jinan, China Beijing, China Richmond, United States Boston, United States Wan-Jie Gu, MSc Gary Y. Yang, MD Nanning, China Loma Linda, United States Zhi Rui Zhou, MD Changchun, China Editorial Board Diego Gonzalez-Rivas, MD, Kevin W. Lobdell, MD Robert Sturm, MSc, PhD James S Allan, MD FECTS Jiade J. Lu, MD, MBA Lijie Tan, MD, Vice Chief Rahul J Anand, MD Cesare Gridelli, MD Giovanni Mariscalco, MD, PhD Kosmas Tsakiridis, MD, PhD Emilio Bajetta, MD, SC Tomas Gudbjartsson, MD, PhD Doug McEvoy, MBBC, FRACP Kenneth WT Tsang, MD, FRCP Peter J Barnes, DM, DSc, FRCP, Don Hayes, Jr, MD, MS, Med Mark J. McKeage, MD Mark I. van Berge Henegouwen, FCCP, FMedSci, FRS Andrea Imperatori, MD Walter McNicholas, MD, FRCPI, MD, PhD J. Patrick Barron, MD Mary Sau Man Ip, MBBS(HK), FRCPC, FCCP Ko Pen Wang, MD, FCCP Bruno R. Bastos, MD MD(HK), FRCP (London, Michael T. Milano, MD, PhD Qun Wang, MD Luca Bertolaccini, MD, PhD Edinburgh, Glasgow), FHKCP, John D. Mitchell, MD Yi-Xiang Wang, MD Peter Calverley, MD FHKAM, FAPSR, FCCP Alyn H Morice MD Zheng Wang, MD Weiguo Cao, MD Richard S. Irwin, MD, Master Akio Niimi, MD, PhD Zhimin Wang, PhD Mario Cazzola, MD FCCP Antonio Passaro, MD Bryan A Whitson, MD, PhD Joe Y Chang, MD, PhD Ki-Suck Jung, MD, PhD Georgios Plataniotis, MD, PhD Yunlong Xia, MD, PhD Yi-han Chen, MD, PhD Alexander Sasha Krupnick, MD David Price, M.B B.Chir, MA, Jin Xu, MS Leo L Cheng, PhD Hyun Koo Kim, MD, PhD DRCOG, FRCGP Ping Yang, MD, PhD Xiangyang Chu, MD Anand Kumar, MD Gui-bin Qiao, MD, PhD Stephen C. Yang, MD Kian Fan Chung, MD, DSc, FRCP Aseem Kumar, PhD Klaus F Rabe, MD, PhD Kazuhiro Yasufuku, MD, PhD Henri G. Colt, MD, FCCP Y. C. Gary Lee, MBChB, PhD, Dominik Rüttinger, MD, PhD, Anthony P.C. Yim, BM Thomas A. D’Amico, MD FCCP, FRCP, FRACP FACS BCh(Oxon), DM(Oxon), Giovanni Dapri, MD, FACS, Mario Leoncini, MD Sundeep Salvi, MD, DNB, PhD, FRCS(Eng) FASMBS Jian Li, MD FCCP Xiuyi Zhi, MD Keertan Dheda, MBBcH, Tianhong Li, MD, PhD Martin Schweiger, MD Caicun Zhou, MD, PhD FCP(SA), FCCP, PhD(Lond), Wenhua Liang, MD Suresh Senan, MD Qinghua Zhou, MD FRCP(Lond) Yang Ling, MD Charles B. Simone, II, MD Zhi-hua Zhu, MD, PhD Peter V. Dicpinigaitis, MD Deruo Liu, MD Yong Song, MD, PhD Leonardo M. Fabbri Lunxu Liu, MD Ross Soo, MD Yoshinosuke Fukuchi, MD, PhD Hui-Wen Lo, PhD Joerg S. Steier, MD (D), PhD (UK) Journal Club Director Editorial Assistants Managing Editor Senior Editors Science Editors Bing Gu, MD Maria Karina, MD, PhD, Katherine L. Ji Grace S. Li (Corresponding Melanie C. He FRCP Editor) Tina C. Pei Parag Prakash Shah, PhD Eunice X. Xu Molly J. Wang Elva S. Zheng Rui Wang Nancy Q. Zhong Table of Contents Preface 181 Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery Keertan Dheda, Loven Moodley Review Article 182 Thoracic surgery for haemoptysis in the context of tuberculosis: what is the best management approach? Semih Halezeroğlu, Erdal Okur 186 The medical and surgical treatment of drug-resistant tuberculosis Gregory L. Calligaro, Loven Moodley, Greg Symons, Keertan Dheda 196 Resurgence of therapeutically destitute tuberculosis: amalgamation of old and newer techniques Ravindra Kumar Dewan, Loven Moodley 202 Aspergilloma and the surgeon Loven Moodley, Jehron Pillay, Keertan Dheda 210 Nontuberculous mycobacterial pulmonary infections Margaret M. Johnson, John A. Odell Original Article 221 Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis Kai-Xiong Liu, Bing Xu, Jie Wang, Jing Zhang, Hai-Bo Ding, Felinda Ariani, Jie-Ming Qu, Qi-Chang Lin Review Article 230 Staging lymph node metastases from lung cancer in the mediastinum Mario D. Terán, Malcolm V. Brock 237 Approach to a solid solitary pulmonary nodule in two different settings—“Common is common, rare is rare” Gabriele B. Murrmann, Femke H.M. van Vollenhoven, Loven Moodley 249 Surgical indications and optimization of patients for resectable esophageal malignancies Joshua C. Grimm, Vicente Valero III, Daniela Molena 258 Indications and interventional options for non-resectable tracheal stenosis Jenny Louise Bacon, Caroline Marie Patterson, Brendan Patrick Madden 271 The anticipation and management of air leaks and residual spaces post lung resection Michael Rolf Mueller, Beatrice A. Marzluf Between You and Me E36 Behind death Cheng-Zhi Wang © Pioneer Bioscience Publishing Company. All rights reserved. Journal of Thoracic Disease, Vol 6, No 3 March 2014 PREFACE Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery This special edition entitled “Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery”
Load more

Recommended publications
  • National Correct Coding Initiative Policy Manual for Medicare Services Revision Date: 1/1/2019
    National Correct Coding Initiative Policy Manual for Medicare Services Revision Date: 1/1/2019 Current Procedural Terminology (CPT) codes, descriptions and other data only are copyright 2018 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS\DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors, prospective payment systems, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for the data contained or not contained herein. TABLE OF CONTENTS FOR NATIONAL CORRECT CODING INITIATIVE POLICY MANUAL FOR MEDICARE SERVICES Introduction Introduction Intro-3 Purpose Intro-3 Policy Manual Background Intro-6 Edit Development and Review Process Intro-7 Sources of Information about NCCI and MUE Intro-9 Correspondence to CMS about NCCI and its Contents Intro-10 Chapter I - General Correct Coding Policies List of Acronyms I-3 A. Introduction I-5 B. Coding Based on Standards of Medical/Surgical I-9 Practice C. Medical/Surgical Package I-12 D. Evaluation and Management (E&M) Services I-17 E. Modifiers and Modifier Indicators I-19 F. Standard Preparation/Monitoring Services for I-27 Anesthesia G. Anesthesia Service Included in the Surgical Procedure I-27 H. HCPCS/CPT Procedure Code Definition I-28 I. CPT Manual and CMS Coding Manual Instructions I-29 J. CPT “Separate Procedure” Definition I-30 K. Family of Codes I-30 L.
    [Show full text]
  • Unusual Case of Non-Resolving Necrotizing Pneumonia: a Last Resort Measure for Cure
    eCommons@AKU Department of Surgery Department of Surgery June 2016 Unusual case of non-resolving necrotizing pneumonia: a last resort measure for cure. Naseem Salahuddin Aga Khan University, [email protected] Naila Baig Ansari Aga Khan University Saulat H. Fatimi Aga Khan University, [email protected] Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg Part of the Surgery Commons Recommended Citation Salahuddin, N., Ansari, N., Fatimi, S. (2016). Unusual case of non-resolving necrotizing pneumonia: a last resort measure for cure.. JPMA: Journal of the Pakistan Medical Association, 66(6), 754-756. Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/566 754 CASE REPORT Unusual case of non-resolving necrotizing pneumonia: A last resort measure for cure Naseem Salahuddin, 1 Naila Baig-Ansari, 2 Saulat Hasnain Fatimi 3 Abstract pathogen of acute CAP, 2,3 and accounts for most cases of To our knowledge, this is an unusual case of a community- slowly resolving pneumonia.The majority of previously acquired pneumonia (CAP) with sepsis secondary to healthy hospitalized patients with severe CAP responded Streptococcus pneumoniae that required lung resection satisfactorily to prompt initiation of appropriate antibiotic for a non-resolving consolidation. A 74 year old previously therapy; however, it is estimated that 10% of hospitalized healthy woman, presented with acute fever, chills and CAP patients have slowly resolving or nonresolving pleuritic chest pain in Emergency Department (ED). A disease. 4 diagnosis of CAP was established with a Pneumonia Severity Index CURB-65 score of 5/5. In the ER, she was Case Report promptly and appropriately managed with antibiotics History: A 74 year old woman who was previously and aggressive supportive therapy.
    [Show full text]
  • FAQ Document
    The Society of Thoracic Surgeons Frequently Asked Questions: General Thoracic Database Version 2.07 December 2008 How to use the “interactive” FAQ Document: 1. To review all clinical questions in an individual section, click on the section title below. Section A: seq# 10 - 190 Section C: seq# 285 - 650 Section E: seq# 770 - 1210 Section B: seq# 200 - 260 Section D: seq# 660 - 750 Section F: seq# 1220 - 1340 2. To review an individual Seq# clinical question, click on the Seq# title below. Participation in both General Thoracic and Adult Cardiac Databases GENERAL STATEMENT #2 Seq# 200: Zubrod Score Seq# 775: Postop Events Seq# 300: WtLoss3Kg Seq# 860: Pneumonia Seq# 310: Category of disease Seq# 930: Other Pulmonary Event Seq# 390: PreOp Chemotherapy Seq# 940: Atrial Arrhythmia Seq# 400: PreOp Thoracic RT Seq# 1020: Anastomotic leak Seq# 430: Other Cormorbidity Seq# 1190: Empyema Seq# 540: Clinical Stage Not Applicable (2.06) Seq# 1200: Other event req. Rx Seq# 725: Reoperation Seq# 1250: 30 Day Status Seq# 740: Procedure Seq# 1280: Chest Tube Out Date Seq# 750: Primary Procedure Seq# 751: Thoracoscopy Approach NEW Date SeqNo FieldName Definition 3/06 Participation in both General We participate in both Adult Cardiac and Yes, enter into both. In the Adult Cardiac DB, the Thoracic and Adult Cardiac General Thoracic Database. Our question primary procedure would be Seq# 1310 pertains to whether the patient should end up OpOCard=Yes; Seq# 2510 ONCAoAn=Yes; Databases in both databases. Scenario--We had a Seq# 2530 ONCArch=Yes; Seq# 2540 patient who had an aortic aneurysm repair ONCDesc=Yes; Seq# 3220 Readm30=Yes; (arch/descending thoracic) and was entered Seq# ReadmRsn=either Pneumonia or other into the Adult Cardiac Database.
    [Show full text]
  • Toman's Tuberculosis Case Detection, Treatment, and Monitoring
    TOMAN’S TUBERCULOSIS TOMAN’S TUBERCULOSIS CASE DETECTION, TREATMENT, AND MONITORING The second edition of this practical, authoritative reference book provides a rational basis for the diagnosis and management of tuberculosis. Written by a number of experts in the field, it remains faithful to Kurt Toman’s original question-and-answer format, with subject matter grouped under the three headings Case detection, Treatment, and Monitoring. It is a testament to the enduring nature of the first edition that so much CASE DETECTION, TREA material has been retained unchanged. At the same time, the new edition has had not only to address the huge resurgence of tuber- culosis, the emergence of multidrug-resistant bacilli, and the special needs of HIV-infected individuals with tuberculosis, but also to encompass significant scientific advances. These changes in the profile of the disease and in approaches to management have inevitably prompted many new questions and answers and given a different complexion to others. Toman’s Tuberculosis remains essential reading for all who need to AND MONITORING TMENT, QUESTIONS learn more about every aspect of tuberculosis – case-finding, manage- ment, and effective control strategies. It provides invaluable support AND to anyone in the front line of the battle against this disease, from ANSWERS programme managers to policy-makers and from medical personnel to volunteer health workers. SECOND EDITION ISBN 92 4 154603 4 WORLD HEALTH ORGANIZATION WHO GENEVA Toman’s Tuberculosis Case detection, treatment, and monitoring – questions and answers SECOND EDITION Edited by T. Frieden WORLD HEALTH ORGANIZATION GENEVA 2004 WHO Library Cataloguing-in-Publication Data Toman’s tuberculosis case detection, treatment, and monitoring : questions and answers / edited by T.
    [Show full text]
  • 114.3 Cmr: Division of Health Care Finance and Policy Ambulatory Care
    114.3 CMR: DIVISION OF HEALTH CARE FINANCE AND POLICY AMBULATORY CARE 114.3 CMR 40.00: RATES FOR SERVICES UNDER M.G.L. c. 152, WORKERS’ COMPENSATION ACT Section 40.01: General Provisions 40.02: General Definitions 40.03: Service and Rate Coverage Provisions 40.04: Provisions Affecting Eligible Providers 40.05: Policies for Individual Service Types 40.06: Fees 40.07: Appendices 40.08: Severability 40.01: General Provisions (1) Scope, Purpose and Effective Date. 114.3 CMR 40.00 governs the payment rates effective April 1, 2009 for purchasers of health care services under M.G.L. c. 152, the Workers’ Compensation Act. Payment rates for services provided by hospitals are set forth in 114.1 CMR 41.00. Program policies relating to medical necessity and clinical appropriateness are determined pursuant to M.G.L. c. 152 and 452 CMR 6.00. (2) Coverage. The payment rates set forth in 114.3 CMR 40.06 are full payment for services provided under M.G.L. c. 152, § 13, including any related administrative or overhead costs. The insurer, employer and health care service provider may agree upon a different payment rate for any service set forth in the fee schedule in 114.3 CMR 40.00. No employee may be held liable for the payment for health care services determined compensable under M.G.L. c. 152, § 13. (3) Administrative Bulletins. The Division may issue administrative bulletins to clarify substantive provisions of 114.3 CMR 40.00, or to publish procedure code updates and corrections. For coding updates and correction, the bulletin will list: (a) new code numbers for existing codes, with the corresponding cross references between existing and new codes numbers; (b) deleted codes for which there are no corresponding new codes; and (c) codes for entirely new services that require pricing.
    [Show full text]
  • Translational Deep Phenotyping of Deaths Related to the COVID-19 Pandemic: Protocol for a Prospective Observational Autopsy Study
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2021-049083 on 27 August 2021. Downloaded from Translational deep phenotyping of deaths related to the COVID-19 pandemic: protocol for a prospective observational autopsy study Mikkel Jon Henningsen ,1 Apameh Khatam- Lashgari,1 Kristine Boisen Olsen,1 Christina Jacobsen,1 Christian Beltoft Brøchner ,2 Jytte Banner1 To cite: Henningsen MJ, ABSTRACT Strengths and limitations of this study Khatam- Lashgari A, Olsen KB, Introduction The COVID-19 pandemic is an international et al. Translational deep emergency with an extreme socioeconomic impact and a ► A standardised, prospective autopsy study on COVID- phenotyping of deaths high mortality and disease burden. The COVID-19 outbreak related to the COVID-19 19- related deaths with systematic data collection. is neither fully understood nor fully pictured. Autopsy studies pandemic: protocol for a ► A multidisciplinary, translational approach elucidat- can help understand the pathogenesis of COVID-19 and has prospective observational ing changes from protein level to whole human. already resulted in better treatment of patients. Structured autopsy study. BMJ Open ► A comprehensive biobank and extensive registry and systematic autopsy of COVID-19- related deaths will 2021;11:e049083. doi:10.1136/ data as an umbrella for planned and future research. bmjopen-2021-049083 enhance the mapping of pathophysiological pathways, not ► The internal control group partly compensates for possible in the living. Furthermore, it provides an opportunity Prepublication history and the observational design. ► to envision factors translationally for the purpose of disease additional supplemental material ► Limited by a selected sample of COVID-19 diseased prevention in this and future pandemics.
    [Show full text]
  • Treatment and Outcomes of Community-Acquired Pneumonia at Canadian Hospitals Research Brian G
    Treatment and outcomes of community-acquired pneumonia at Canadian hospitals Research Brian G. Feagan,* Thomas J. Marrie,† Catherine Y. Lau,‡ Recherche Susan L. Wheeler,‡ Cindy J. Wong,* Margaret K. Vandervoort* From *the London Clinical Abstract Trials Research Group, London, Ont.; †the Background: Community-acquired pneumonia is a common disease with a large Department of Medicine, economic burden. We assessed clinical practices and outcomes among patients University of Alberta, with community-acquired pneumonia admitted to Canadian hospitals. Edmonton, Alta.; Methods: A total of 20 hospitals (11 teaching and 9 community) participated. Data and ‡Janssen–Ortho from the charts of adults admitted during November 1996, January 1997 and Incorporated, Toronto, Ont. March 1997 were reviewed to determine length of stay (LOS), admission to an intensive care unit and 30-day in-hospital mortality. Multivariate analyses exam- This article has been peer reviewed. ined sources of variability in LOS. The type and duration of antibiotic therapy and the proportion of patients who were treated according to clinical practice CMAJ 2000;162(10):1415-20 guidelines were determined. Results: A total of 858 eligible patients were identified; their mean age was 69.4 (standard deviation 17.7) years. The overall median LOS was 7.0 days (in- terquartile range [IQR] 4.0–11.0 days); the median LOS ranged from 5.0 to 9.0 days across hospitals (IQR 6.0–7.8 days). Only 22% of the variability in LOS could be explained by known factors (disease severity 12%; presence of chronic obstructive lung disease or bacterial cause for the pneumonia 2%; hospital site 7%).
    [Show full text]
  • Respiratory Tract Infections in the Tropics
    9.1 CHAPTER 9 Respiratory Tract Infections in the Tropics Tim J.J. Inglis 9.1 INTRODUCTION Acute respiratory infections are the single most common infective cause of death worldwide. This is also the case in the tropics, where they are a major cause of death in children under five. Bacterial pneumonia is particularly common in children in the tropics, and is more often lethal. Pulmonary tuberculosis is the single most common fatal infection and is more prevalent in many parts of the tropics due to a combination of endemic HIV infection and widespread poverty. A lack of diagnostic tests, limited access to effective treatment and some traditional healing practices exacerbate the impact of respiratory infection in tropical communities. The rapid urbanisation of populations in the tropics has increased the risk of transmitting respiratory pathogens. A combination of poverty and overcrowding in the peri- urban zones of rapidly expanding tropical cities promotes the epidemic spread of acute respiratory infection. PART A. INFECTIONS OF THE LOWER RESPIRATORY TRACT 9.2 PNEUMONIA 9.2.1 Frequency Over four million people die from acute respiratory infection per annum, mostly in developing countries. There is considerable overlap between these respiratory deaths and deaths due to tuberculosis, the single commonest fatal infection. The frequency of acute respiratory infection differs with location due to host, pathogen and environmental factors. Detailed figures are difficult to find and often need to be interpreted carefully, even for tuberculosis where data collection is more consistent. But in urban settings the enormity of respiratory infection is clearly evident. Up to half the patients attending hospital outpatient departments in developing countries have an acute respiratory infection.
    [Show full text]
  • Emblemhealth's Pre-Authorization List
    EmblemHealth's Pre-authorization List This is a complete list of all services requiring a Prior Approval for HIP members or a Pre-Certification for GHI members* (jointly referred to as "pre-authorization") subject to their benefit plan's coverage for all places of service, including Office (POS 11). The list accounts for EmblemHealth's medical policies, medical technology database, provider manual, and special utilization management programs. Pre-authorization is not a guarantee of payment. Payment is subject to a member's eligibility for benefits on the date of service. Emergency services do not require a pre-authorization. *GHI PPO City of New York employees and non-Medicare eligible retirees with GHI PPO benefits will be managed by Empire BCBS for inpatient and outpatient services. To see what needs authorization, use their look-up tool: https://www.empireblue.com/wps/portal/ehpprovider. CPT/ HCPCS Description Code 0008M Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin- embedded (FFPE) tissue, prognostic algorithm reported as a risk score 00640 Anesthesia for manipulation of the spine or for closed procedures on the cervical, thoracic or lumbar spine 0085T Breath test for heart transplant rejection 0100T Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy 0195T Arthrodesis, pre-sacral interbody technique, disc space preparation, discectomy, without instrumentation, with image guidance, includes
    [Show full text]
  • Endoscopy Matrix
    Endoscopy Matrix CPT Description of Endoscopy Diagnostic Therapeutic Code (Surgical) 31231 Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) X 31233 Nasal/sinus endoscopy, diagnostic with maxillary sinusoscopy (via X inferior meatus or canine fossa puncture) 31235 Nasal/sinus endoscopy, diagnostic with sphenoid sinusoscopy (via X puncture of sphenoidal face or cannulation of ostium) 31237 Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or X debridement (separate procedure) 31238 Nasal/sinus endoscopy, surgical; with control of hemorrhage X 31239 Nasal/sinus endoscopy, surgical; with dacryocystorhinostomy X 31240 Nasal/sinus endoscopy, surgical; with concha bullosa resection X 31241 Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery X 31253 Nasal/sinus endoscopy, surgical; with ethmoidectomy, total (anterior X and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed 31254 Nasal/sinus endoscopy, surgical; with ethmoidectomy, partial (anterior) X 31255 Nasal/sinus endoscopy, surgical; with ethmoidectomy, total (anterior X and posterior 31256 Nasal/sinus endoscopy, surgical; with maxillary antrostomy X 31257 Nasal/sinus endoscopy, surgical; with ethmoidectomy, total (anterior X and posterior), including sphenoidotomy 31259 Nasal/sinus endoscopy, surgical; with ethmoidectomy, total (anterior X and posterior), including sphenoidotomy, with removal of tissue from the sphenoid sinus 31267 Nasal/sinus endoscopy, surgical; with removal of
    [Show full text]
  • 2017 Pulmonary Coding and Payment Quick Reference
    2017 Coding & Payment Quick Reference Select Pulmonary Procedures Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding or site of service requirements. The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options. Medicare Physician, Hospital Outpatient, and ASC Payments The bronchoscopy procedures listed below (except CPT® Codes 31622, 31660, and 31661) all include a diagnostic bronchoscopy when performed by the same physician. 2017 Medicare National Average Payment RVUs Physician‡,2 Facility3 CPT® Total Total Hospital Code Description Work In-Office In-Facility ASC Code1 Office Facility Outpatient Biopsy 31625 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, 3.11 9.43 4.53 $338 $163 $1,270† $569 when performed; with bronchial or endobronchial biopsy(s), single or multiple sites 31628 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, 3.55 10.00 5.09 $359 $183 $2,431† $1,117 when performed; with transbronchial lung biopsy(s), single lobe 31632 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, 1.03 1.84 1.42 $66 $51 $0 $0 when performed; with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure)* Cytology and Brush 31622 Bronchoscopy, rigid or flexible, including fluoroscopic guidance, 2.53 6.86 3.81 $246 $137 $1,270† $569 when performed; diagnostic,
    [Show full text]
  • Community Acquired Pneumonia
    Community Acquired Pneumonia MELISSA PALMER AGACNP Objectives Know the target population for the 2019 American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA) Community-acquired Pneumonia (CAP) guidelines 2019 Know when to perform testing for CAP: sputum cultures, blood cultures, Legionella and pneumococcal urinary antigen testing, influenza testing, and procalcitonin Be able to discuss the utilization of steroids in patients with CAP Know the selection of initial empiric antibiotic therapy for community-acquired pneumonia and duration of treatment for inpatients Criteria for hospitalization versus the need for ICU admission in adults diagnosed with CAP based on Pneumonia severity index (PSI) compared to CURB-65 Discuss the differences between the 2019 and 2007 ATS/IDSA Community-acquired Pneumonia Guidelines. COVID-19 Identify and Isolate. Pneumonia and CAP definition Pneumonia Infection of the alveoli, distal airways and the interstitium of the lung. Clinical: a new or changing radiographic density (infiltrate). Usually accompanied by constitutional symptoms of lung inflammation. Community Acquired Pneumonia acquired outside the hospital Signs and symptoms of pneumonia with radiographic confirmation *Patient must not have been hospitalized nor resided in a long-term-care facility for, at minimum, 14 days prior to the onset of symptoms Impact of Pneumonia leading infectious cause of hospitalization and death among U.S. adults more than 1.5 million adults hospitalized annually medical costs exceeding
    [Show full text]